Aptar Pharma inaugurates Congers site expansion
Aptar Pharma Congers, courtesy of Aptar Pharma.
New site will be used to complete premium injectable elastomeric component manufacturing.
Aptar Pharma’s site expansion in Congers, NY will be inaugurated on 20 March by Stephan Tanda, AptarGroup’s President and CEO, Salim Haffar, President of Aptar Pharma, and Alex Theodorakis, President Aptar Pharma North America. Several Aptar Pharma customers in North America have been invited to attend this inaugural event.
Aptar Pharma’s newly-expanded, state-of-the-art manufacturing capabilities will be used to complete premium injectable elastomeric component manufacturing, enabling Aptar Pharma to better serve its North American pharmaceutical customers.
“The new expansion supports growth in three directions,” explained Bas van Buijtenen, President, Injectables Division, Aptar Pharma. “It adds capacity to our network of global manufacturing sites and will be equipped with the latest technologies to meet growing quality requirements. The proximity to our North American customer base improves our service and responsiveness.”
Following this event, Aptar Pharma will welcome current and future customers and partners during the Drug, Chemical & Associated Technologies Association (DCAT) Week and Interphex, at booth 1734.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.